Group 1 - The core viewpoint of the article highlights the significant stock price increase of BGM, which rose by 11.78% on December 17, reaching $5.6 per share, with a total market capitalization of $1.03 billion [1] - As of March 31, 2025, BGM reported total revenue of $14.31 million, reflecting a year-on-year growth of 13.92%, while the net profit attributable to shareholders was -$0.8612 million, a decrease of 307.79% compared to the previous year [1] - BGM, formerly known as Qilian International Holdings Group, is based in Chengdu, China, and focuses on innovative sectors such as biopharmaceuticals, bio-extraction, and healthcare [1] Group 2 - The company's product range includes raw materials for oxytetracycline, licorice preparations, and crude heparin sodium, which are essential for both human antibiotics and the global livestock industry [1] - Crude heparin sodium is processed by downstream companies into refined heparin sodium and injectable heparin sodium solutions, serving as a primary anticoagulant [1] - Licorice preparations, such as compound licorice tablets, are used as cough remedies and supplied to retail pharmacies [1]
博美集团上涨11.78%，报5.6美元/股，总市值10.30亿美元